Refractory Mantle Cell Lymphoma clinical trials

Explore recruiting refractory mantle cell lymphoma clinical trials.

Recruiting refractory mantle cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Mantle Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Bcl 2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Germany, Poland, France, Spain, Belgium, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Efficacy of Polatuzumab, Bendamustine and Rituximab in patients with relapsed/refractory mantle cell lymphoma- A single center phase II trial

Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

France, Spain, Germany, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Controlled, Open-label, Multicenter, Inferentially Seamless Phase 2/3 Study of Ibrutinib in Combination With Rituximab Versus Physician’s Choice of Lenalidomide Plus Rituximab or Bortezomib Plus Rituximab in Participants with Relapsed or Refractory Mantle Cell Lymphoma

Czechia, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A PHASE III, OPEN-LABEL, MULTICENTER RANDOMIZED STUDY EVALUATING GLOFITAMAB AS A SINGLE AGENT VERSUS INVESTIGATOR’S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA

Italy, France, Sweden, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapy

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Refractory Mantle Cell Lymphoma trials by city

Refractory Mantle Cell Lymphoma in Toronto Refractory Mantle Cell Lymphoma in Vancouver Refractory Mantle Cell Lymphoma in Montreal Refractory Mantle Cell Lymphoma in Calgary Refractory Mantle Cell Lymphoma in Edmonton Refractory Mantle Cell Lymphoma in Ottawa Refractory Mantle Cell Lymphoma in Winnipeg Refractory Mantle Cell Lymphoma in Quebec City Refractory Mantle Cell Lymphoma in Hamilton Refractory Mantle Cell Lymphoma in Kitchener Refractory Mantle Cell Lymphoma in London Refractory Mantle Cell Lymphoma in Halifax Refractory Mantle Cell Lymphoma in New York Refractory Mantle Cell Lymphoma in Los Angeles Refractory Mantle Cell Lymphoma in Chicago Refractory Mantle Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease